Nordic Naturals Ultimate Omega 1280 mg Review

Yes — and this is the entire reason Ultimate Omega beats the generic fish-oil aisle. Dyerberg 2010 (PMID 20638827) ran the head-to-head bioavailability comparison and found 30-50% higher EPA+DHA blood incorporation from TG/rTG vs ethyl ester at identical doses. That means Nordic Naturals at 1280 mg/serving delivers roughly what a 1800 mg/serving EE bottle would. The rTG form also oxidises slower and produces a fraction of the fishy-burp signal of EE — so adherence over 12 weeks is dramatically higher. The $5-10/month premium over generic EE is the smallest high-leverage upgrade in the supplement category.

Only if your specific endpoint is mood, depression, or REDUCE-IT-style EPA-driven cardiovascular protocol. Sublette 2011 (PMID 21939614) established that EPA-dominance (≥2:1 EPA:DHA) is required for the antidepressant effect — Carlson Elite EPA at 1600 mg pure EPA is the cleanest expression of that. But Ultimate Omega's 650 EPA / 450 DHA balance is the right ratio for general-health Omega-3 Index correction, cognitive co-support, and as the default first bottle. If you don't have a specific EPA-dominant goal, the balanced ratio is correct.

The premium buys three things: form (rTG vs Now Foods' undifferentiated TG-blend), documentation (a Certificate of Analysis you can pull by lot number on Nordic's site vs Now Foods' results on request), and the lemon softgel that keeps people taking it. For the budget-constrained buyer, Now Foods is the right answer. One correction to an earlier version of this answer: Ultimate Omega is not IFOS-listed — the certifier's database shows Nordic Naturals under IGEN non-GMO testing only (checked Oct 3, 2026) — so the premium buys the brand's own per-lot certificate, not an independent batch database.

Not according to the certifier's own database. On Oct 3, 2026 Nutrasource — the company that runs IFOS — listed Nordic Naturals under its IGEN non-GMO program only (Ultimate Omega appears there as non-GMO tested) and returned no IFOS entry for the brand. An earlier version of this review said otherwise and has been corrected. What the label itself carries is '3rd Party Purity Tested' and 'Friend of the Sea Certified Sustainable'. To check your own bottle, find the lot number near the expiry date and enter it at nordic.com/nordic-promise — the brand returns a Certificate of Analysis covering potency, purity and oxidation for that lot.

You can, but you'll fall outside the trial window. One softgel delivers 640 mg total omega-3s — below the 1 g/day general-health floor. The 2-softgel serving is built around the 1280 mg/day dose that lands in the Omega-3 Index correction range. If swallowing 2 softgels is genuinely difficult, swap to Sports Research Triple Strength (#3), a single softgel with 1,040 mg total omega-3 — same rTG form, just consolidated.

Felt effects are unreliable for omega-3 — most users feel nothing in the first 4-8 weeks even when bloodwork shows the supplement is working. The honest answer: Omega-3 Index rises measurably by week 4-8 and hits steady state at week 12. Triglyceride drops are detectable by week 6-12 on bloodwork. Mood signals from EPA-dominant formulations land at week 8-16. If you ran 2 softgels/day for 12 weeks and saw no biomarker movement on a follow-up panel, you're either a non-responder or your baseline was already at target. Don't chase felt effects; track Omega-3 Index or triglycerides at week 12 if you can.

1. [1] Dyerberg 2010 (TG vs EE bioavailability) PMID 20638827 — Bioavailability of marine n-3 fatty acid formulations. Direct head-to-head bioavailability comparison: triglyceride (TG) and re-esterified triglyceride (rTG) forms showed 30-50% higher EPA+DHA incorporation into blood lipids than ethyl ester (EE) at identical doses. The trial that anchors Ultimate Omega's entire value proposition — the rTG form is the bioavailability standard the supplement category should default to.
2. [2] Mozaffarian 2011 PMID 22051327 — Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Comprehensive review of omega-3 cardiovascular effects: triglyceride reduction of 10-33% at 2-4 g/day, modest blood pressure reduction, anti-arrhythmic effects, reduced platelet aggregation. The reference review for the dose justification behind 2-4 g/day cardiovascular protocols — Ultimate Omega lands inside this window at 2-3 servings/day.
3. [3] Harris 2008 (Omega-3 Index) PMID 15208005 — The omega-3 index: a new risk factor for death from coronary heart disease?. Defined the Omega-3 Index (RBC EPA+DHA as % of total fatty acids) as a cardiovascular risk biomarker. An index of 8%+ associated with the lowest CHD mortality; modern Western average sits at 4-5%. The biomarker most fish-oil intervention trials now use — Ultimate Omega at 2 softgels/day for 12 weeks reliably moves the index toward the 8% target.
4. [4] Bhatt 2019 (REDUCE-IT) PMID 30415628 — Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. 4 g/day icosapent ethyl over 4.9 years reduced major adverse cardiovascular events by 25% vs placebo in statin-treated high-risk adults. The strongest non-statin CV outcome evidence in the omega-3 literature — anchors the rationale for 2-4 g/day EPA+DHA cardiovascular protocols. Ultimate Omega at 3 softgels/day approximates a balanced version of this dose.
5. [5] Serhan 2014 (resolvins) PMID 24899309 — Pro-resolving lipid mediators are leads for resolution physiology. Mapped the resolvin and protectin biosynthesis pathway from EPA + DHA, demonstrating that omega-3 fatty acids drive active resolution of inflammation through specialised pro-resolving mediators (SPMs) — mechanistically distinct from NSAIDs. The molecular mechanism behind Ultimate Omega's anti-inflammatory effect at trial doses.